Logo

Viatris and Biocon Launched Abevmy (biosimilar, bevacizumab) for the Treatment of Cancer in Canada

Share this
Viatris and Biocon Launched Abevmy (biosimilar, bevacizumab) for the Treatment of Cancer in Canada

Viatris and Biocon Launched Abevmy (biosimilar, bevacizumab) for the Treatment of Cancer in Canada

Shots:

  • The companies launched Abevmy (biosimilar bevacizumab) referencing Avastin for the treatment of multiple types of cancer in Canada. Abevmy is the third oncology biosimilar & has been co-developed by Viatris and Biocon Biologics
  • Abevmy is available to patients in the form of 100mg/4 mL single-use vials and 400mg/4 mL single-use vials. The companies have launched Viatris Advocate program that enables patients to access Abevmy & provides support and resources for patients, caregivers, and healthcare providers
  • Under the Feb 2022 agreement with Viatris, Biocon Biologics will acquire Viatris' biosimilars portfolio globally, including Abevmy for ~$3.3B. The. The transaction is expected to close in H2’22

Ref:  Viatris | Image: Viatris 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions